Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2010

01.12.2010 | Invited Commentary

The androgen receptor in breast cancer: learning from the past

verfasst von: Michaela J. Higgins, Antonio C. Wolff

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Excerpt

Care of the cancer patient is becoming increasingly individualized. At the fulcrum of such therapeutic decision-making lies a relevant and accurate understanding of unique patient characteristics and preferences, and of tumor biology. In a pure sense, prognostic factors reflect tumor biology that may be used to estimate outcome independent of systemic treatment, whereas predictive factors reflect a relative resistance or sensitivity to specific therapy(ies) and are increasingly used to select optimal treatments for an individual patient. Perhaps the best and oldest example of a biomarker with proven clinical utility is the estrogen receptor alpha (ER), the expression of which on breast tumors has served both as a prognostic and predictive biomarker for the last three decades [1]. The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 2005 overview clearly demonstrated that tamoxifen substantially reduces the risk for breast cancer recurrence and death across all age groups in patients with ER-positive early-stage breast cancer, whereas patients with ER-negative disease do not benefit from tamoxifen [2, 3]. ER status also predicts response to endocrine therapy in the metastatic setting [4]. In this issue of Breast Cancer Research and Treatment, a well designed and thorough study by Castellano et al. [5] explores the concept of androgen receptor (AR) as a novel prognostic factor in ER-positive breast cancer, and suggests that it may have additional clinical utility in identifying a better prognosis subgroup of luminal B breast cancers. …
Literatur
1.
Zurück zum Zitat Hammond EH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for immunohistochemical testing of estrogen/progesterone receptors in breast cancer. J Clin Oncol (in press) Hammond EH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for immunohistochemical testing of estrogen/progesterone receptors in breast cancer. J Clin Oncol (in press)
2.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
3.
Zurück zum Zitat Clarke M, Coates AS, Darby SC et al (2008) Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371:29–40CrossRefPubMed Clarke M, Coates AS, Darby SC et al (2008) Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371:29–40CrossRefPubMed
4.
Zurück zum Zitat Osborne CK, Yochmowitz MG, Knight WA III et al (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884–2888CrossRefPubMed Osborne CK, Yochmowitz MG, Knight WA III et al (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884–2888CrossRefPubMed
5.
Zurück zum Zitat Castellano I, Allia E, Accortanzo V et al (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. doi:10.1007/s10549-010-0761-y Castellano I, Allia E, Accortanzo V et al (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. doi:10.​1007/​s10549-010-0761-y
6.
Zurück zum Zitat Agoff SN, Swanson PE, Linden H et al (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120:725–731CrossRefPubMed Agoff SN, Swanson PE, Linden H et al (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120:725–731CrossRefPubMed
7.
Zurück zum Zitat Yeh S, Hu YC, Wang PH et al (2003) Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med 198:1899–1908CrossRefPubMed Yeh S, Hu YC, Wang PH et al (2003) Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med 198:1899–1908CrossRefPubMed
8.
Zurück zum Zitat Schippinger W, Regitnig P, Dandachi N et al (2006) Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 449:24–30CrossRefPubMed Schippinger W, Regitnig P, Dandachi N et al (2006) Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 449:24–30CrossRefPubMed
9.
Zurück zum Zitat Moinfar F, Okcu M, Tsybrovskyy O et al (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98:703–711CrossRefPubMed Moinfar F, Okcu M, Tsybrovskyy O et al (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98:703–711CrossRefPubMed
10.
Zurück zum Zitat Kuenen-Boumeester V, Van der Kwast TH, Claassen CC et al (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A:1560–1565CrossRefPubMed Kuenen-Boumeester V, Van der Kwast TH, Claassen CC et al (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A:1560–1565CrossRefPubMed
11.
Zurück zum Zitat Ogawa Y, Hai E, Matsumoto K et al (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 13:431–435CrossRefPubMed Ogawa Y, Hai E, Matsumoto K et al (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 13:431–435CrossRefPubMed
12.
Zurück zum Zitat Clarke BL, Khosla S (2009) New selective estrogen and androgen receptor modulators. Curr Opin Rheumatol 21:374–379CrossRefPubMed Clarke BL, Khosla S (2009) New selective estrogen and androgen receptor modulators. Curr Opin Rheumatol 21:374–379CrossRefPubMed
13.
Zurück zum Zitat Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMed Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMed
14.
Zurück zum Zitat McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235CrossRefPubMed McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235CrossRefPubMed
15.
Zurück zum Zitat Peters AA, Buchanan G, Ricciardelli C et al (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69:6131–6140CrossRefPubMed Peters AA, Buchanan G, Ricciardelli C et al (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69:6131–6140CrossRefPubMed
16.
Zurück zum Zitat Gonzalez-Angulo AM, Stemke-Hale K, Palla SL et al (2009) Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15:2472–2478CrossRefPubMed Gonzalez-Angulo AM, Stemke-Hale K, Palla SL et al (2009) Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15:2472–2478CrossRefPubMed
17.
Zurück zum Zitat Sanga S, Broom BM, Cristini V et al (2009) Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Med Genomics 2:59CrossRefPubMed Sanga S, Broom BM, Cristini V et al (2009) Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Med Genomics 2:59CrossRefPubMed
Metadaten
Titel
The androgen receptor in breast cancer: learning from the past
verfasst von
Michaela J. Higgins
Antonio C. Wolff
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0864-5

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research and Treatment 3/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.